Utility of p63 in the differential diagnosis of atypical fibroxanthoma and spindle cell squamous cell carcinoma

Journal of Cutaneous Pathology

Volumn 36, Issue 5, 2009, Pages 543-547

  Gleason, Briana C ^a   Calder, Kenneth B ^b   Cibull, Thomas L ^a   Thomas, Antoinette B ^c   Billings, Steven D ^c   Morgan, Michael B ^b   Hiatt, Kim M ^a   Smoller, Bruce R ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN; KERATIN; PROTEIN P63; PROTEIN S 100;

ADULT; AGED; ARTICLE; ATYPICAL FIBROXANTHOMA; CLINICAL ARTICLE; DIFFERENTIAL DIAGNOSIS; FEMALE; FIBROXANTHOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROTEIN EXPRESSION; SPINDLE CELL; SPINDLE CELL CARCINOMA;

AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; FEMALE; HISTIOCYTOMA, BENIGN FIBROUS; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; S100 PROTEINS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 63849320575     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2008.01099.x     Document Type: Article

References (31)

1. Wick MR, Fitzgibbon J, Swanson PE. Cutaneous sarcomas and sarcomatoid neoplasms of the skin. Semin Diagn Pathol 1993 10 : 148.
2. Longacre TA, Egbert BM, Rouse RV. Desmoplastic and spindle-cell malignant melanoma. An immunohistochemical study. Am J Surg Pathol 1996 20 : 1489.
3. Bishop PW, Menasce LP, Yates AJ, Win NA, Banerjee SS. An immunophenotypic survey of malignant melanomas. Histopathology 1993 23 : 159.
4. Sigel JE, Skacel M, Bergfeld WF, House NS, Rabkin MS, Goldblum JR. The utility of cytokeratin 5/6 in the recognition of cutaneous spindle cell squamous cell carcinoma. J Cutan Pathol 2001 28 : 520.
5. Heintz PW, White CR Jr. Diagnosis: atypical fibroxanthoma or not? Evaluating spindle cell malignancies on sun damaged skin: a practical approach. Semin Cutan Med Surg 1999 18 : 78.
6. Monteagudo C, Calduch L, Navarro S, Joan-Figueroa A, Llombart-Bosch A. CD99 immunoreactivity in atypical fibroxanthoma: a common feature of diagnostic value. Am J Clin Pathol 2002 117 : 126.
7. Hultgren TL, DiMaio DJ. Immunohistochemical staining of CD10 in atypical fibroxanthomas. J Cutan Pathol 2007 34 : 415.
8. Weedon D, Williamson R, Mirza B. CD10, a useful marker for atypical fibroxanthomas. Am J Dermatopathol 2005 27 : 181.
9. Jensen K, Wilkinson B, Wines N, Kossard S. Procollagen 1 expression in atypical fibroxanthoma and other tumors. J Cutan Pathol 2004 31 : 57.
10. Senoo M, Pinto F, Crum CP, McKeon F. p63 is essential for the proliferative potential of stem cells in stratified epithelia. Cell 2007 129 : 523.
11. Kaufmann O, Fietze E, Mengs J, Dietel M. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol 2001 116 : 823.
12. Lewis JS, Ritter JH, El-Mofty S. Alternative epithelial markers in sarcomatoid carcinomas of the head and neck, lung, and bladder-p63, MOC-31, and TTF-1. Mod Pathol 2005 18 : 1471.
13. Wang TY, Chen BF, Yang YC, et al. Histologic and immunophenotypic classification of cervical carcinomas by expression of the p53 homologue p63: a study of 250 cases. Hum Pathol 2001 32 : 479.
14. Takeuchi Y, Tamura A, Kamiya M, Fukuda T, Ishikawa O. Immunohistochemical analyses of p63 expression in cutaneous tumours. Br J Dermatol 2005 153 : 1230.
15. Dotto JE, Glusac EJ. p63 is a useful marker for cutaneous spindle cell squamous cell carcinoma. J Cutan Pathol 2006 33 : 413.
16. Di Como CJ, Urist MJ, Babayan I, et al. p63 expression profiles in human normal and tumor tissues. Clin Cancer Res 2002 8 : 494.
17. Reis-Filho JS, Simpson PT, Martins A, Preto A, Gartner F, Schmitt FC. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch 2003 443 : 122.
18. Cates JM, Dupont WD, Barnes JW, et al. Markers of epithelial-mesenchymal transition and epithelial differentiation in sarcomatoid carcinoma: utility in the differential diagnosis with sarcoma. Appl Immunohistochem Mol Morphol 2008 16 : 251.
19. Lee CH, Espinosa I, Jensen KC, et al. Gene expression profiling identifies p63 as a diagnostic marker for giant cell tumor of the bone. Mod Pathol 2008 21 : 531.
20. Kempson RL, McGavran MH. Atypical fibroxanthomas of the skin. Cancer 1964 17 : 1463.
21. Fretzin DF, Helwig EB. Atypical fibroxanthoma of the skin. A clinicopathologic study of 140 cases. Cancer 1973 31 : 1541.
22. Enzinger FM. Atypical fibroxanthoma and malignant fibrous histiocytoma (questions to the editorial board). Am J Dermatopathol 1979 1 : 185.
23. Helwig EB, May D. Atypical fibroxanthoma of the skin with metastasis. Cancer 1986 57 : 368.
24. Connective tissue tumors. In McKee PH, Calonje E, Granter SR, eds. Pathology of the skin with clinical correlations, 3rd ed. London : Elsevier Mosby, 2005 1757.
25. Mirza B, Weedon D. Atypical fibroxanthoma: a clinicopathological study of 89 cases. Australas J Dermatol 2005 46 : 235.
26. Dei Tos AP, Maestro R, Doglioni C, et al. Ultraviolet-induced p53 mutations in atypical fibroxanthoma. Am J Pathol 1994 145 : 11.
27. Sakamoto A, Oda Y, Itakura E, et al. Immunoexpression of ultraviolet photoproducts and p53 mutation analysis in atypical fibroxanthoma and superficial malignant fibrous histiocytoma. Mod Pathol 2001 14 : 581.
28. Santa Cruz DJ. Tumors of the skin. In Fletcher CDM, ed. Diagnostic histopathology of tumors, 3rd ed. London : Churchill Livingstone, 2007 1491.
29. Cassarino DS, Derienzo DP, Barr RJ. Cutaneous squamous cell carcinoma: a comprehensive clinicopathologic classification. Part one. J Cutan Pathol 2006 33 : 191.
30. Luzar B, Wang W-L, Asher R, Lazar AJ, Bracko M, Calonje E. Spindle cell carcinoma of the skin: a clinicopathological analysis of 30 cases. Mod Pathol 2008 21 : 97A.
31. Kanitakis J, Chouvet B. Expression of p63 in cutaneous metastases. Am J Clin Pathol 2007 128 : 753.